AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2153355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 times daily for 4 months)
Number of subjects: 25
Study 351886 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadaver donor pretreatment with 5 g of methylprednisolone and 7 g of cyclophosphamide
Number of subjects: 52
Study 351886 — intervention group
Group type: COMPARATOR
Intervention: Nonpretreated kidneys
Number of subjects: 52
Study 30319049 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic group (D)
Number of subjects: 165
Study 30319049 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic group (ND)
Number of subjects: 165
Study 30319049 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic group (D) with early recanalization
Number of subjects: 165
Study 30319049 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic group (ND) with early recanalization
Number of subjects: 165
Study 30319049 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic group (ND) without early recanalization
Number of subjects: 165
Study 30319049 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic group (D) without early recanalization
Number of subjects: 165
Study 30319049 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete recanalization at 24 h
Number of subjects: 165
Study 27018511 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion group (knee flexed mildly < 30 degrees)
Number of subjects: 108
Study 27018511 — intervention group
Group type: COMPARATOR
Intervention: Extension group (knee fully extended)
Number of subjects: 108
Study 27018511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (leg elevated 25 cm for 72 hours)
Number of subjects: 108
Study 25041383 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel patch applied directly on the affected area three times within the first 24 hours, followed by three additional patches over the next 3 days.
Number of subjects: 23
Study 25041383 — intervention group
Group type: COMPARATOR
Intervention: Usual care (adjustment of the denture's margins)
Number of subjects: 23
Study 25041383 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel patch
Number of subjects: 23
Study 25041383 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control lesions)
Number of subjects: 23
Study 23865644 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy enrolled and delivered HIV risk reduction information to IDUs
Number of subjects: 0
Study 23865644 — intervention group
Group type: COMPARATOR
Intervention: Pharmacy only enrolled IDUs
Number of subjects: 0
Study 23865644 — intervention group
Group type: COMPARATOR
Intervention: Pharmacy did not engage IDUs
Number of subjects: 0
Study 21757278 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (4 injections of 2 mL of 10% dextrose and 1 mL of 2% mepivacaine each 6 weeks apart)
Number of subjects: 12
Study 21757278 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 injections of 2 mL of saline solution and 1 mL of 2% mepivacaine each 6 weeks apart)
Number of subjects: 12
Study 19840635 — intervention group
Group type: EXPERIMENTAL
Intervention: Final rinse with BioPure MTAD
Number of subjects: 30
Study 19840635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracanal medication with 2% chlorhexidine gel (CHX)
Number of subjects: 30
Study 19840635 — intervention group
Group type: COMPARATOR
Intervention: Canal preparation with 1.3% NaOCl
Number of subjects: 30
Study 16759839 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg every 8h
Number of subjects: 96
Study 16759839 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriostatic CFR
Number of subjects: 96
Study 16759839 — intervention group
Group type: EXPERIMENTAL
Intervention: Bactericidal CFR
Number of subjects: 96
Study 15373930 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody ATM-027
Number of subjects: 0
Study 11769578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (n = 41)
Number of subjects: 136
Study 11769578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (n = 16)
Number of subjects: 136
Study 11769578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (n = 19)
Number of subjects: 136
Study 11769578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (n = 30)
Number of subjects: 136
Study 11769578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5 (n = 14)
Number of subjects: 136
Study 11769578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 6 (n = 10)
Number of subjects: 136
Study 11769578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 7 (n = 6)
Number of subjects: 136
Study 11769578 — intervention group
Group type: COMPARATOR
Intervention: Group 1 and Group 3
Number of subjects: 136
Study 11769578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2
Number of subjects: 136
Study 11769578 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking TSHRAb activity
Number of subjects: 136
Study 9652559 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg infusion on day 0 and day 4)
Number of subjects: 380
Study 9652559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 9652559 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 380
Study 8115491 — intervention group
Group type: EXPERIMENTAL
Intervention: Veinotonyl 75
Number of subjects: 42
Study 8115491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3481627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin alone
Number of subjects: 0
Study 3481627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin combined with fosfomycin
Number of subjects: 0
Study 3481627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin combined with vancomycin
Number of subjects: 0
Study 3481627 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin alone
Number of subjects: 0
Study 3481627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (1 and 4 mg/l)
Number of subjects: 0
Study 3481627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin combined with fosfomycin (one of three strains)
Number of subjects: 0
Study 3481627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin with fosfomycin (two of three strains)
Number of subjects: 0
Study 3481627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin with vancomycin (three strains)
Number of subjects: 0
Study 3481627 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 400 mg ofloxacin with subsequent doses of 200 mg
Number of subjects: 0
Study 31758735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 200 mg/ledipasvir 45 mg (8-week treatment)
Number of subjects: 22
Study 31758735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 200 mg/ledipasvir 45 mg (12-week treatment)
Number of subjects: 22
Study 29476702 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app CDST
Number of subjects: 144
Study 29476702 — intervention group
Group type: EXPERIMENTAL
Intervention: Print CDST
Number of subjects: 144
Study 29476702 — intervention group
Group type: COMPARATOR
Intervention: Control (no CDST)
Number of subjects: 144
Study 27329084 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C‐MeAIB PET
Number of subjects: 34
Study 27329084 — intervention group
Group type: COMPARATOR
Intervention: 18F‐FDG PET
Number of subjects: 34
Study 27329084 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 34
Study 24178584 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-centered (CC) intervention
Number of subjects: 678
Study 24178584 — intervention group
Group type: EXPERIMENTAL
Intervention: Family School Partnership (FSP)
Number of subjects: 678
Study 24178584 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 678
Study 22414490 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game balance board program
Number of subjects: 40
Study 22414490 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi
Number of subjects: 40
Study 22414490 — intervention group
Group type: COMPARATOR
Intervention: Standard balance exercise program
Number of subjects: 40
Study 22414490 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample (all interventions)
Number of subjects: 40
Study 20207825 — intervention group
Group type: EXPERIMENTAL
Intervention: GH plus raloxifene (R; 60 mg/d)
Number of subjects: 21
Study 20207825 — intervention group
Group type: EXPERIMENTAL
Intervention: GH plus 17beta‐estradiol (E(2); 2 mg/d)
Number of subjects: 21
Study 20207825 — intervention group
Group type: COMPARATOR
Intervention: GH therapy alone (0.5 mg/d)
Number of subjects: 21
Study 18540803 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Number of subjects: 155
Study 18540803 — intervention group
Group type: COMPARATOR
Intervention: efavirenz
Number of subjects: 155
Study 16108036 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 20
Study 16108036 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch
Number of subjects: 20
Study 12685518 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 12685518 — intervention group
Group type: EXPERIMENTAL
Intervention: Other stimulant medications
Number of subjects: 0
Study 12685518 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatments
Number of subjects: 0
Study 12685518 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic trials with a duration or follow-up period of 12 months or more
Number of subjects: 0
Study 10049982 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic index meal
Number of subjects: 12
Study 10049982 — intervention group
Group type: COMPARATOR
Intervention: Medium glycemic index meal
Number of subjects: 12
Study 10049982 — intervention group
Group type: COMPARATOR
Intervention: Low glycemic index meal
Number of subjects: 12
Study 7585848 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (contents from a 30‐mg capsule placed in a tablespoonful of applesauce)
Number of subjects: 24
Study 7585848 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (an intact 30‐mg capsule)
Number of subjects: 24
Study 7585848 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A
Number of subjects: 24
Study 7585848 — intervention group
Group type: COMPARATOR
Intervention: Regimen B
Number of subjects: 24
Study 7585848 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 24
Study 2106837 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (1‐(2‐tetrahydrofuryl)‐5‐fluorouracil mixed with uracil) orally at a daily dose of 300 mg
Number of subjects: 29
Study 2106837 — intervention group
Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 29
Study 1164876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine treatment
Number of subjects: 106
Study 1164876 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 106
Study 1164876 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (high-risk patients)
Number of subjects: 106
Study 1164876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine treatment (low-risk patients)
Number of subjects: 106
Study 31152911 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 88 μg
Number of subjects: 0
Study 31152911 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 175 μg
Number of subjects: 0
Study 31152911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31152911 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 0
Study 29178937 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 11 mg/kg/day
Number of subjects: 0
Study 29178937 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 14 mg/kg/day
Number of subjects: 0
Study 29178937 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 17 mg/kg/day
Number of subjects: 0
Study 29178937 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 20 mg/kg/day
Number of subjects: 0
Study 29178937 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin doses (11, 14, 17, 20 mg/kg/day)
Number of subjects: 0
Study 25209456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 2%
Number of subjects: 30
Study 25209456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25209456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 1%
Number of subjects: 30
Study 25209456 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5%
Number of subjects: 30
Study 23948958 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose statin therapy
Number of subjects: 826
Study 23948958 — intervention group
Group type: COMPARATOR
Intervention: Low-dose/no statins
Number of subjects: 826
Study 23948958 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions in saphenous vein grafts, malapposed stents, overlap >3 mm, complex coronary anatomy
Number of subjects: 826
Study 23948958 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions in saphenous vein grafts, underexpanded or malapposed stents, history of myocardial infarction
Number of subjects: 826
Study 21930596 — intervention group
Group type: EXPERIMENTAL
Intervention: IH with losartan (AT(1) receptor antagonist)
Number of subjects: 9
Study 21930596 — intervention group
Group type: COMPARATOR
Intervention: IH with placebo medication
Number of subjects: 9
Study 21930596 — intervention group
Group type: COMPARATOR
Intervention: Sham IH
Number of subjects: 9
Study 20061584 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (60 mg/kg/dose)
Number of subjects: 97
Study 20061584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 20061584 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 97
Study 16426275 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-type headache (TH)
Number of subjects: 114
Study 16426275 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine (M)
Number of subjects: 114
Study 16426275 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (NC)
Number of subjects: 114
Study 15561035 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep pericardial suture technique (group 1)
Number of subjects: 20
Study 15561035 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted apical suction device (group 2)
Number of subjects: 20
Study 12160759 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridium-192 intracoronary radiation therapy (IRT)
Number of subjects: 130
Study 9202916 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride 100 mg
Number of subjects: 75
Study 9202916 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1 mg
Number of subjects: 75
Study 9202916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 75
Study 9202916 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 75
Study 7955971 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily isophane (Protaphane)
Number of subjects: 0
Study 7955971 — intervention group
Group type: EXPERIMENTAL
Intervention: Three times daily soluble insulin (Actrapid)
Number of subjects: 0
Study 7955971 — intervention group
Group type: COMPARATOR
Intervention: Protaphane therapy
Number of subjects: 0
Study 7955971 — intervention group
Group type: COMPARATOR
Intervention: Actrapid therapy
Number of subjects: 0
Study 7955971 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (both regimens)
Number of subjects: 0
Study 3297124 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (375 mg over 3 days)
Number of subjects: 12
Study 3297124 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (circa 40 mg i.v. over 60 min)
Number of subjects: 12
Study 3297124 — intervention group
Group type: COMPARATOR
Intervention: VIP infusion (6 pmol kg-1 min-1)
Number of subjects: 12
Study 30335205 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent group (n = 20) received monetary incentives for negative breathalyzer samples.
Number of subjects: 40
Study 30335205 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent group (n = 20) received matched monetary payments regardless of alcohol content.
Number of subjects: 40
Study 30335205 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent group (n = 20)
Number of subjects: 40
Study 30335205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 27060177 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical activity programme
Number of subjects: 947
Study 27060177 — intervention group
Group type: COMPARATOR
Intervention: Health education programme
Number of subjects: 947
Study 24972455 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline
Number of subjects: 8
Study 24972455 — intervention group
Group type: COMPARATOR
Intervention: Non-essential AA mixture (NEAA)
Number of subjects: 8
Study 23776115 — intervention group
Group type: EXPERIMENTAL
Intervention: Exothermic mattresses (EMs)
Number of subjects: 72
Study 23776115 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene bags (PBs) without EMs
Number of subjects: 72
Study 21092183 — intervention group
Group type: EXPERIMENTAL
Intervention: Job aids-focused intervention
Number of subjects: 0
Study 18212574 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrathecal analgesia with a 28-gauge catheter
Number of subjects: 429
Study 18212574 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural analgesia with a 20-gauge catheter
Number of subjects: 429
Study 16680933 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg, 3 times daily
Number of subjects: 610
Study 16680933 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg, once daily
Number of subjects: 610
Study 16680933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 15238047 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants who saw an object hidden inside a container and were removed from the disappearance locale for 24 hr
Number of subjects: 14
Study 15238047 — intervention group
Group type: COMPARATOR
Intervention: Control infants who saw no disappearance
Number of subjects: 14
Study 15238047 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants who returned to see the container in a different room
Number of subjects: 14
Study 11549412 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DSIS observer ratings on participants
Number of subjects: 59
Study 11549412 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DSIS observer ratings on confederates
Number of subjects: 59
Study 11549412 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis of 2DSIS
Number of subjects: 59
Study 9002102 — intervention group
Group type: EXPERIMENTAL
Intervention: C-aPDT vaccine (Chiron/Biocine)
Number of subjects: 2000
Study 9002102 — intervention group
Group type: COMPARATOR
Intervention: wDPT vaccine (Connaught)
Number of subjects: 2000
Study 9002102 — intervention group
Group type: COMPARATOR
Intervention: Lederle aPDT vaccine
Number of subjects: 2000
Study 8428857 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching session for parents
Number of subjects: 26
Study 8428857 — intervention group
Group type: COMPARATOR
Intervention: Control group (parents who did not attend the course)
Number of subjects: 26
Study 3036724 — intervention group
Group type: EXPERIMENTAL
Intervention: sequential intermittent polychemotherapy (sq CT) after surgery
Number of subjects: 56
Study 3036724 — intervention group
Group type: COMPARATOR
Intervention: standard chemotherapy (CT) after surgery
Number of subjects: 56
Study 31343630 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge Test Feedback Intervention (KTFI) and routine education
Number of subjects: 100
Study 31343630 — intervention group
Group type: COMPARATOR
Intervention: Routine patient education
Number of subjects: 100
Study 28069068 — intervention group
Group type: EXPERIMENTAL
Intervention: as-needed budesonide/formoterol 160/4.5 μg
Number of subjects: 7864
Study 28069068 — intervention group
Group type: COMPARATOR
Intervention: placebo bid plus as-needed terbutaline 0.4 mg
Number of subjects: 7864
Study 28069068 — intervention group
Group type: COMPARATOR
Intervention: budesonide 200 μg bid plus as-needed terbutaline 0.4 mg
Number of subjects: 7864
Study 26049550 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop (HCL) system
Number of subjects: 29
Study 26049550 — intervention group
Group type: COMPARATOR
Intervention: Medtronic MiniMed 530G with threshold suspend (control group)
Number of subjects: 29
Study 23644758 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music before surgery (Music group)
Number of subjects: 100
Study 23644758 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control group)
Number of subjects: 100
Study 21298283 — intervention group
Group type: COMPARATOR
Intervention: 25 Hz rTMS
Number of subjects: 10
Study 19515182 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.9-5.0 mmol/l FPG target
Number of subjects: 244
Study 19515182 — intervention group
Group type: COMPARATOR
Intervention: 4.4-6.1 mmol/l FPG target
Number of subjects: 244
Study 17919090 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 DNA viral load (DNA‐VL) in TR mothers
Number of subjects: 66
Study 17919090 — intervention group
Group type: COMPARATOR
Intervention: HIV‐1 DNA viral load (DNA‐VL) in NTR mothers
Number of subjects: 66
Study 17919090 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of TR and NTR mothers
Number of subjects: 66
Study 14985996 — intervention group
Group type: EXPERIMENTAL
Intervention: MAX training at 100% of maximum inspiratory pressure (MIP) for 6 weeks
Number of subjects: 66
Study 14985996 — intervention group
Group type: EXPERIMENTAL
Intervention: SUB training at 80% of maximum inspiratory pressure (MIP) for 6 weeks
Number of subjects: 66
Study 14985996 — intervention group
Group type: COMPARATOR
Intervention: Control group (no inspiratory training)
Number of subjects: 66
Study 11231370 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 250 mg every day
Number of subjects: 61
Study 11231370 — intervention group
Group type: COMPARATOR
Intervention: Control (no furosemide)
Number of subjects: 61
Study 10095796 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg once daily)
Number of subjects: 60
Study 10095796 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg once daily)
Number of subjects: 60
Study 8142829 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial taping of the patella
Number of subjects: 14